title: Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma.
abstract: The best treatment strategy for patients with locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC) remains the subject of considerable debate. This report presents a case of a 58-year-old woman with locally advanced unresectable PDAC who was treated with sequential FOLFIRINOX for 8 cycles followed by chemoradiation, and continues to show durable disease control 18 months later. The respective roles of systemic therapy and chemoradiation for locally advanced PDAC are discussed, including optimal sequencing of these modalities, recent improvements in chemotherapy, and the question of whether radiotherapy improves survival outcomes in this disease context.
authors.affiliation: From the Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.
authors.forename: Pelin
authors.initials: P
authors.lastname: Cinar
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Ko
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D021441:Carcinoma, Pancreatic Ductal / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome